Alderley Park, UK, 4thDecember 2018– Blueberry Therapeutics won the coveted ‘Company of the Year’ award after another remarkable year of progress and innovation. 2018 has seen many great achievements for Blueberry Therapeutics including the completion of £10m Series B Fundraising with investment from China Medical Venture Investment (HK) Limited alongside the recently announced BB2603 Phase I/II trial reaching all primary endpoints in patients with both onychomycosis (fungal nail infection) and concomitant tinea pedis (athletes’ foot).

The 17thannual Bionow Awards were held this year at the Mere Golf Resort and Spa on Thursday 29thNovember. The companies involved in the awards are all leaders in the North’s life sciences sector, which is worth more than £13bn to the economy.

David Cook, Chief Scientific Officer at Blueberry Therapeutics said he was ‘truly honoured by the award and the recognition of the team’s outstanding expertise and achievement’. He believes that the award supports Blueberry Therapeutics’ overarching vision ‘to bring high value, innovative medicines to the market’ and is excited to share future programme developments in 2019.

Geoff Davison, CEO of Bionow, congratulated Blueberry Therapeutics and the other winners on the night and said: “The 2018 Awards reflect the superb efforts by companies in the Life Sciences sector in the North to innovate and commercialise great ideas and IP into new medicines and treatments.”

Rowena Burns, Chair of sponsor Manchester Science Partnerships, added: “This has been a landmark year for the life sciences sector in the North. Confidence amongst investors is high, and company growth rates are strong.

The 17thannual awards were a fantastic success and accurately showcased the excellence and outstanding achievements of leading Northern life science companies.